AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.Referred to as “Royalty Management Co” and “Biopharma Co,” the two companies’ different business models enable investors to align their investment philosophies and portfolio allocation with each company’s strategic opportunities and financial objectives.“Anaptys is strategically positioned with multiple attractive, high-potential assets…,” said Daniel Faga, pre ...